Updated on 9 December 2014
GVK offers a full blown drug repurposing collaborative research services starting from in-silico hypothesis generation to IND enabling studies under one roof
Singapore: The drug repurposing platform called GRIP (GVK Bio Repurposing Integrated Platform) is a combination of several GVK Bio proprietary and several public domain databases.
It calls for reinvestigating the marketed drugs, clinical and/or pre-clinical candidates and can be applied to many different compounds including those that have failed to show efficacy in late stage clinical trials.
GVK offers a full blown drug repurposing collaborative research services starting from in-silico hypothesis generation to IND enabling studies under one roof.
In addition, GRIP is capable of addressing drug-based, target-based and disease-based repurposing requests and also for generic drugs and innovative compounds (drugs with patent validity, shelved, and pre-clinical stage).
Underlying the Drug Repositioning process is a set of 8 distinct algorithms that allow for unbiased interpretation of the input data to predict alternative indications.
Supplementing GRIP is a team of PhD level scientists and clinicians who help in the accurate interpretation of the data.